Emmaus Life Sciences, Inc. (ticker: EMMA) is an OTC-listed pharma company. DredgeCap's structured extraction of EMMA's SEC filings surfaces 16 active risk signals, including 14 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. EMMA reported $12.45M in revenue and -$7.49M for the period ending 2025-12-31, with operating cash flow of -$11K. Cash and equivalents stood at $2.13M (up 53.1% year-over-year). Total assets of $21.44M are exceeded by total liabilities of $85.04M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
EMMA Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Emmaus Life Sciences, Inc. (EMMA) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.